Next Treatments
Back to Eczema

KT-621

TypePill StagePhase 2 Latest updateNov 24, 2025Phase 2 study started

What stands out

New approach in eczema

  • Breaks down STAT6, a relay inside cells that carries immune signals to genes
Derived from NCT06945458 · UniProt P42226 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Apr 17, 2025. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Nov 24, 2025Phase 2 trial startedA Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07217015
  • Nov 10, 2025Phase 1 trial completedSafety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) ClinicalTrials.gov NCT06945458
  • Apr 17, 2025Phase 1 trial startedSafety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) ClinicalTrials.gov NCT06945458

Sources

Trials